Nantes University, CHU Nantes, Pharmacy, Nantes 44000, France.
Nantes University, CHU Nantes, Pharmacy, Nantes 44000, France.
Ann Pharm Fr. 2023 Jun;81(4):596-603. doi: 10.1016/j.pharma.2022.11.003. Epub 2022 Nov 12.
The objective of this study was to assess the relevance of proton pump inhibitors prescribing in patients entering a ward with a clinical pharmacist and therefore identifying inappropriate prescribing.
A prospective study was conducted for 4 months. Patients admitted to the hospital for elective or emergency surgery, who had medication reconciliation performed by the clinical pharmacy team and who were prescribed proton pump inhibitors before admission were included. The indication for the proton pump inhibitors was collected from the patient or inferred from the medical history. The compliance of the prescriptions with the marketing authorization indications and the duration of treatment and dose was analyzed. The indications were classified into 3 groups: compliant with marketing authorization, off label but relevant use, and strictly off label use.
During the study period, 100 patients were included among whom only 29% had a PPI prescription that did fully comply with the recommendations. Among the twenty-three prescriptions that did not comply with the recommendations in terms of indication, 15 were not relevant at all. Among the 65 prescriptions relevant for indication, 36 were not compliant with dose or duration recommendations. 59% of the total number of patients reported that they had never tried to stop treatment.
Our study highlights the need for regular reassessment of proton pump inhibitors prescriptions. Multi-disciplinary collaboration on the appropriate use of this class of medication as well as increased awareness among general practitioners and hospital doctors is essential.
本研究旨在评估在配备临床药师的病房中为患者开具质子泵抑制剂的相关性,从而确定不适当的开具处方情况。
进行了为期 4 个月的前瞻性研究。纳入因择期或急诊手术而住院、由临床药学团队进行药物重整且入院前开具质子泵抑制剂的患者。质子泵抑制剂的适应证从患者处收集或从病史中推断。分析了处方与药品上市许可适应证的一致性以及治疗持续时间和剂量。适应证分为 3 组:符合药品上市许可适应证、标签外但合理使用、严格标签外使用。
在研究期间,共纳入 100 例患者,其中只有 29%的患者开具的质子泵抑制剂处方完全符合建议。在 23 例不符合适应证建议的处方中,有 15 例完全不相关。在 65 例适应证相关的处方中,有 36 例不符合剂量或持续时间建议。59%的患者报告他们从未尝试过停药。
我们的研究强调了需要定期重新评估质子泵抑制剂处方。多学科合作以促进此类药物的合理使用,以及提高全科医生和医院医生的认识至关重要。